Citi predicted that leading Chinese pharma/ biopharma stocks would have a chance to beat expectations with their 1H25 results thanks to external licensing deals and strong growth in innovative drug sales. Meanwhile, leading Contract Development and Manufacturing Organizations (CDMOs) are also likely to deliver better-than-expected 1H25 results because of strong order backlogs.Major companies under the WuXi series were hyped up this morning (24th). WUXI XDC (02268.HK) -2.200 (-3.813%) Short selling $15.38M; Ratio 2.946% opened 2.1% higher and climbed to a historic high of HKD57.7 in early trading. It last traded at HKD56.85, up 5.96%, with a volume of 5.7191 million shares, involving HKD320 million.Related NewsBofAS Lifts WUXI APPTEC's TP to HKD115.7, Reiterating Buy RatingWUXI BIO (02269.HK) -0.850 (-2.640%) Short selling $297.81M; Ratio 19.357% busted above its 52-week record this morning to a nearly one-and-a-half-year high of HKD30.15. It last printed at HKD29.85, up 3.83%, with a volume of 40.277 million shares, involving HKD1.181 billion.After opening flat, WUXI APPTEC (02359.HK) -4.000 (-3.784%) Short selling $577.63M; Ratio 37.655% also managed to break above its 52-week record to an over one-and-a-half-year high of HKD96. It was last at HKD95.45, up 2.47%, with a volume of 4.0343 million shares, involving HKD383 million.(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-08-01 16:25.)